The logic behind the approach rests on a decade of progress in proteomics, the large-scale study of the protein complement of biological systems. Unlike the genome, which is essentially fixed at conception, the proteome is dynamic: it shifts with infection, stress, exercise, disease, and, crucially, with age itself. Researchers have shown that machine-learning models trained on thousands of plasma protein measurements can predict chronological age with remarkable accuracy, and that the difference between predicted and actual age—sometimes called proteomic age acceleration—correlates with frailty, multimorbidity, and mortality risk. These proteomic clocks are conceptually analogous to the epigenetic clocks based on DNA methylation that transformed aging research in the 2010s, but they offer distinct advantages for interventional trials: blood proteins are readily sampled repeatedly, they respond to physiological change on shorter timescales than DNA methylation marks, and many of the proteins involved are themselves drug targets or biomarkers already familiar to the pharmaceutical industry.

What the new study demonstrates is that this technology can survive contact with the realities of clinical trial design. The researchers integrated multiple proteomic aging clocks into the analytical framework of a phase 2a trial, the earliest stage at which a therapeutic candidate is tested in patients or at-risk volunteers to gather preliminary evidence of biological activity. Rather than treating biological age estimation as an exploratory afterthought, the team built the clocks into the statistical evaluation plan from the outset, defining in advance how changes in proteomic age would be measured, how measurement noise would be handled, and how multiple clock outputs could be combined to give a coherent picture of whether an intervention was shifting the biology of aging in a favorable direction.

The emphasis on simultaneous assessment is the study’s most distinctive contribution. Different aging clocks, trained on different protein sets and different cohorts, capture partly overlapping and partly distinct facets of the aging process—one model may be more sensitive to inflammatory pathways, another to metabolic or hepatic changes, a third to renal or cardiovascular decline. By deploying a suite of clocks in parallel rather than betting on a single algorithm, the trial design allows investigators to ask not merely whether an intervention changes a number, but whether it changes the underlying biology in a way that is consistent across independent measures of aging. Convergence across multiple clocks provides a form of internal replication that a single biomarker cannot offer, while divergence among clocks can itself be informative, pointing to organ-specific or pathway-specific effects that would otherwise be invisible.

Technically, the integration demanded solutions to several stubborn problems. Proteomic measurements are sensitive to pre-analytical variables: the choice of assay platform, the timing of blood draws, fasting status, and even the season of sample collection can shift protein concentrations. Longitudinal interpretation requires that the analytical pipeline distinguish true within-person change from batch effects and ordinary biological fluctuation. The study addressed these challenges by anchoring the clocks to repeated baseline sampling, applying rigorous quality control to the proteomic data, and using statistical models that estimate change within individuals rather than relying solely on comparisons between treatment and control groups at a single time point. This within-person framing is essential for short trials, because it dramatically increases statistical power when each participant serves as their own reference for the direction and magnitude of biological aging.

The broader significance of the work lies in what it could do to the economics of geroscience. Developing drugs that target aging has long been caught in a regulatory and commercial Catch-22: regulators generally approve treatments for diseases, not for aging itself, because aging lacks an agreed clinical endpoint; without approved indications, investment in geroprotective therapies has lagged. Biomarkers that can credibly demonstrate a slowing of biological aging over months rather than decades offer a path through this impasse. If proteomic clocks can be validated as surrogate endpoints or at least as robust pharmacodynamic markers, early-phase trials of candidate geroprotectors—whether repurposed drugs such as rapamycin and its analogues, senolytic agents that clear senescent cells, or novel molecules designed around aging pathways—become faster, smaller, and far cheaper to run.

The phase 2a setting is precisely where such markers earn their keep. Phase 2a studies are designed to detect signals of biological activity, not to prove clinical benefit, and a biomarker that reliably responds to an intervention’s mechanism of action is exactly the kind of signal these trials exist to find. Embedding proteomic clocks at this stage creates a screening funnel: interventions that show consistent effects across multiple aging measures can be advanced to larger trials with confidence, while those that leave the proteome untouched can be deprioritized before expensive late-stage development. In effect, the clocks function as a biological readout of geroprotection, analogous to how viral load measurements transformed the early development of antiretroviral therapies.

Important caveats remain, and the authors and the field are careful to acknowledge them. A change in a proteomic aging clock is not yet proof that a therapy extends healthspan or lifespan; the clocks are validated against age-related outcomes in observational data, and demonstrating that an intervention moves the biomarker is only the first step toward showing that it changes disease trajectories. Calibration across diverse populations is another open question, since proteomic aging signatures can vary with ancestry, sex, socioeconomic factors, and baseline health status, and a clock optimized in one cohort may miscalibrate in another. Standardization across assay platforms and laboratories will also be necessary before proteomic age becomes a measure that regulators and clinicians can compare across studies. The new work does not resolve these issues single-handedly, but it establishes a concrete, tested framework within which they can be addressed trial by trial.

Even so, the moment feels like an inflection point. The geroscience field has spent years generating compelling animal data on interventions that delay aging, only to face a translational bottleneck at the human frontier. The integration of proteomic aging clocks into a real phase 2a clinical trial shows that the measurement problem—long the field’s most fundamental limitation—is tractable with current technology. If subsequent trials replicate and extend this framework, the result could be a virtuous cycle in which better biomarkers enable faster trials, faster trials attract greater investment, and greater investment produces the interventions that finally move the needle on human healthspan. Aging, for the first time, is being measured in the clinic on the timescale of a clinical trial, and that change may prove as important as any single therapeutic candidate now in development.

Subject of Research: Proteomic aging clocks integrated into a phase 2a clinical trial for geroprotective assessment

Article Title: Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment

Article References: Zhavoronkov, A., Galkin, F., Chen, S., Ren, F., Aliper, A., Durymanov, M., Sidorenko, D., Cui, H., Han, J.-D. J., Xu, H., Liu, X., Xu, Z., Kuppe, C., Austin Argentieri, M., Ying, K., Goeminne, L. J. E., Moqri, M., Tyshkovskiy, A., & Gladyshev, V. N. (2026). Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03286-y

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03286-y

Keywords: proteomic aging clocks, biological age, geroprotection, phase 2a trial, geroscience, biomarkers, plasma proteomics, aging interventions, healthspan, clinical trial design, machine learning, surrogate endpoints